In healthcare, we spend years evaluating medicines under carefully controlled clinical conditions. That rigor is absolutely essential.
But patients don’t live in the carefully controlled clinical conditions of clinical trials. They live in the complexity of the real world.
And for people managing chronic conditions, the treatment itself can become another burden to manage. A medicine may provide important clinical benefit while also introducing practical challenges—from complicated preparation and frequent procedures to travel, storage, administration, and disruption of everyday routines.
Those burdens can become even more consequential when the patient is a child.
Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet chronic illness can reshape daily life not only for the child, but for the entire household, as parents and caregivers manage treatment schedules, appointments, logistics, costs, and the emotional weight that can come with them.
That is why even seemingly small improvements in how a medicine fits into everyday life can matter enormously.
Kenya experienced that firsthand with her family.
After her oldest daughter was diagnosed with Central Precocious Puberty, or CPP, treatment required frequent injections that became a source of stress for the family.
When her younger daughter, Liana, later received the same diagnosis, Kenya wanted to explore an option that might reduce some of that burden. Liana began treatment with a different form of injectable prescription gonadotropin releasing hormone (GnRH) medicine used for the treatment of children with central precocious puberty (CPP), which is administered twice yearly.
For Kenya and her family, reducing the frequency of injections changed the rhythm of treatment. Instead of frequent procedures becoming a recurring part of family life, treatment occupied far fewer moments in Liana’s year.
Jessica and Pablo faced a very different condition, but a similar challenge with their daughter, Viviana.
Born prematurely at 26 weeks, Viviana spent four months in the NICU and later developed severe epilepsy. Because she could not swallow solid pills, her parents relied on custom-compounded liquid zonisamide.
That often meant driving nearly an hour each way to obtain medication. The compounded medicine had a short expiration period, required refrigeration, and added complexity to travel and everyday family routines.
When Viviana’s neurologist introduced a different form of zonisamide, a commercially available zonisamide oral suspension, much of that logistical burden changed.
Instead of traveling long distances for compounded medication, Pablo could obtain a shelf-stable liquid from a nearby pharmacy. Her parents also described a meaningful change in Viviana’s attitude toward taking her medicine. What had previously been a difficult daily medicinal experience became a routine she approached much more positively.
The diseases were different. The families were different. But the underlying lesson was remarkably similar.
Children need treatments designed for the realities of childhood. And families need medicines that fit into daily life rather than forcing daily life to revolve around treatment.
That principle sits at the heart of how we think about Azurity Pharmaceuticals.
Our mission is to redefine medicine for the real world. But that mission is not simply an aspiration. It has shaped the operating model we have built.
We look for places where there is a gap between the medicine and the reality of the patient who relies on it. Sometimes the opportunity is formulation. Sometimes it is dosing frequency, administration, or access. And sometimes it is recognizing that an established medicine can be made meaningfully better for a particular patient population.
The specific solution varies. The discipline does not.
Understand where treatment makes life harder. Understand the patient. Then ask whether we have the capabilities to make it meaningfully better.
That may sound simple. Doing it repeatedly is not.
It requires the ability to identify opportunities others may overlook and then bring together the formulation, development, regulatory, commercial, market access, and lifecycle capabilities needed to turn those opportunities into medicines that can make a meaningful difference in patients’ lives.
That is the pharmaceutical operating model we have built at Azurity.
And it is important because the opportunity extends far beyond any one medicine or disease.
Medicines are necessarily evaluated in controlled clinical settings, but that cannot be the end of how we think about them. Once a therapy enters the real world, it encounters human behavior, family schedules, school, travel, work, preferences, physical limitations, access barriers, and countless other realities that rarely fit neatly into a protocol.
Understanding those realities can reveal opportunities that clinical endpoints alone may not fully capture. And seemingly small changes in formulation, delivery, administration, or dosing can sometimes make a meaningful difference in how treatment fits into a patient’s life.
Liana and Viviana have different diseases, different treatment journeys, and different families. But their stories remind us of something fundamental.
For a child, real life means school, family, travel, birthdays, friendships, and everything else that makes childhood childhood.
Medicine should fit into that life—not force that life to fit around medicine.
That’s what redefining medicine for the real world means to me.
Kids should have the freedom to focus on being kids.
